WO2018181860A1 - 末梢神経障害の治療剤又は予防剤 - Google Patents
末梢神経障害の治療剤又は予防剤 Download PDFInfo
- Publication number
- WO2018181860A1 WO2018181860A1 PCT/JP2018/013536 JP2018013536W WO2018181860A1 WO 2018181860 A1 WO2018181860 A1 WO 2018181860A1 JP 2018013536 W JP2018013536 W JP 2018013536W WO 2018181860 A1 WO2018181860 A1 WO 2018181860A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- therapeutic
- peripheral neuropathy
- general formula
- prophylactic agent
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 149
- 230000000069 prophylactic effect Effects 0.000 title claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 31
- 208000027232 peripheral nervous system disease Diseases 0.000 title abstract description 5
- -1 cyclic amine Chemical class 0.000 claims abstract description 115
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 61
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 201000004339 autoimmune neuropathy Diseases 0.000 claims description 17
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 claims description 17
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 15
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 230000002503 metabolic effect Effects 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 13
- 230000007823 neuropathy Effects 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 12
- 206010062346 Congenital neuropathy Diseases 0.000 claims description 11
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 10
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000003449 preventive effect Effects 0.000 claims description 8
- 230000003210 demyelinating effect Effects 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims description 4
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 3
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 3
- 229940124350 antibacterial drug Drugs 0.000 claims description 3
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 3
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 36
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 5
- 229940125904 compound 1 Drugs 0.000 description 117
- 241000700159 Rattus Species 0.000 description 64
- 230000000694 effects Effects 0.000 description 60
- 208000004454 Hyperalgesia Diseases 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 40
- 230000006698 induction Effects 0.000 description 38
- 239000003981 vehicle Substances 0.000 description 35
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 33
- 229960004316 cisplatin Drugs 0.000 description 33
- 210000003594 spinal ganglia Anatomy 0.000 description 25
- 239000000243 solution Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 18
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 17
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 17
- 229960001052 streptozocin Drugs 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000023105 myelination Effects 0.000 description 13
- 229960001756 oxaliplatin Drugs 0.000 description 13
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 13
- 206010053552 allodynia Diseases 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 10
- 102000047918 Myelin Basic Human genes 0.000 description 10
- 101710107068 Myelin basic protein Proteins 0.000 description 10
- 238000000692 Student's t-test Methods 0.000 description 10
- 230000008506 pathogenesis Effects 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 229960001467 bortezomib Drugs 0.000 description 9
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000003501 co-culture Methods 0.000 description 9
- 230000007830 nerve conduction Effects 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 210000000578 peripheral nerve Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003007 myelin sheath Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000483002 Euproctis similis Species 0.000 description 6
- 102000006386 Myelin Proteins Human genes 0.000 description 6
- 108010083674 Myelin Proteins Proteins 0.000 description 6
- 206010029240 Neuritis Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 210000005012 myelin Anatomy 0.000 description 5
- 210000004116 schwann cell Anatomy 0.000 description 5
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 4
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229960002866 duloxetine Drugs 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960001233 pregabalin Drugs 0.000 description 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000033952 Paralysis flaccid Diseases 0.000 description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 229960000366 emtricitabine Drugs 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 208000028331 flaccid paralysis Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 238000009177 immunoglobulin therapy Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000033600 microtubule polymerization or depolymerization Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000003156 vasculitic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 0 *C(CC(c1ncc[n]1*)O*)=O Chemical compound *C(CC(c1ncc[n]1*)O*)=O 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 101150053137 AIF1 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 description 1
- 101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 101710156102 Non-fluorescent flavoprotein Proteins 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800004191 Peptide P2 Proteins 0.000 description 1
- 102100030564 Peroxisomal membrane protein 2 Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960000531 abacavir sulfate Drugs 0.000 description 1
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940111120 gold preparations Drugs 0.000 description 1
- 239000009896 gosha-jinki-gan Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000009181 shakuyaku-kanzoh-toh Substances 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a therapeutic or prophylactic agent for peripheral neuropathy.
- Peripheral neuropathy is caused by damage to nerve cells (axon or nerve cell body) or myelin sheath (Schwann cell) constituting peripheral nerve.
- nerve cells axon or nerve cell body
- myelin sheath axon or nerve cell body
- histopathology axonal degeneration and myelin degeneration are observed, and physiologically, functional abnormalities such as a decrease in nerve conduction velocity occur.
- Non-Patent Document 1 Damage to peripheral nerve cells or myelin sheath, sensory neuropathy showing symptoms such as numbness of the limbs (abnormal sensation), illusion, dullness, pain or hearing loss, muscle weakness / atrophy, flaccid paralysis Or thought to cause peripheral neuropathy such as motor neuropathy showing symptoms such as reduction or disappearance of deep tendon reflexes, or autonomic neuropathy showing symptoms such as constipation, abdominal pain, sweating disorders, dysuria or orthostatic hypotension (Non-Patent Document 1).
- Non-patent Document 1 discloses a method for treating peripheral neuropathy. Although these symptoms of peripheral neuropathy are rarely life-threatening, they have a great impact on the daily life of patients and significantly reduce the quality of life.
- Peripheral neuropathy can be broadly classified according to the cause of nerve damage, and representative examples include drug-induced peripheral neuropathy, autoimmune peripheral neuropathy, metabolic peripheral neuropathy, hereditary peripheral neuropathy, and the like.
- Non-Patent Document 2 Examples of drugs that cause drug-induced peripheral neuropathy include anticancer drugs, antiviral drugs, antibacterial drugs, antituberculosis drugs, antiarrhythmic drugs, hyperlipidemia drugs, immunosuppressants, gout drugs, and the like.
- drug-induced peripheral neuropathy sensory disorders such as pain are often the main subject, and the disorder may remain even after withdrawal (Non-Patent Document 2).
- anticancer agents have a high incidence of peripheral neuropathy, which makes it difficult to continue cancer treatment.
- Analgesics eg, pregabalin, gabapentin or ketamine
- antiepileptic drugs eg, lamotrigine, carbamazepine, phenytoin, valproic acid or clonazepam
- antidepressants to relieve symptoms of peripheral neuropathy induced by anticancer drugs (For example, amitriptyline, imipramine, clomipramine or duloxetine), Chinese herbal medicine (eg, Goshajinkigan or Shakuyakukanzoto), vitamin B preparation (eg, B6 or B12), etc. are administered, but are induced by anticancer agents.
- An effective method for treating or preventing peripheral neuropathy has not been established (Non-patent Document 1).
- Non-patent Document 3 chemotherapeutic agent-induced peripheral neuropathy
- Non-patent Document 3 pregabalin, gabapentin, nortriptyline, except for duloxetine, among the drugs recommended for use in neuropathic pain treatment guidelines
- Non-Patent Documents 4 to 5 formulated by the International Society for Pain and the European Neurological Society, respectively.
- amitriptyline is effective for neuropathic pain induced by anticancer drugs (Non-Patent Documents 6 to 7).
- Autoimmune peripheral neuropathy is a neuropathy caused by autoimmunity against components of peripheral nerves, such as Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy. : CIDP), multifocal motor neuropathy (MMN), and neuropathy associated with abnormal proteinemia (paraproteinomic neuropathy: PPN) (Non-patent Document 8).
- GBS is thought to be triggered by the infection of pathogenic microorganisms such as viruses and bacteria, and may develop after vaccination against infection of these pathogenic microorganisms.
- the main feature is paralysis of the limbs and loss of deep reflexes, often accompanied by sensory disturbances such as pain and abnormal sensations. In severe cases, there are cases where death occurs due to respiratory problems or autonomic disturbances.
- There are many subtypes of GBS, and acute inflammatory demyelinating neuritis, acute motor axon type neuritis, acute motor sensory axon type neuritis, Fisher syndrome, etc. are known (non-patent literature) 9).
- CIDP is a chronic or relapsing / remitting autoimmune peripheral neuropathy that causes muscle weakness and sensory impairment.
- MMN and PPN are diseases similar to CIDP.
- MMN is characterized by myopathy without sensory impairment (Non-Patent Document 10).
- PPN is caused by abnormal growth of a single immunoglobulin and is characterized by slowly progressive sensory neuropathy (Non-Patent Document 11).
- Intravenous immunoglobulin therapy and simple plasma exchange therapy are effective as treatment methods for autoimmune peripheral neuropathy (Non-patent Document 12).
- simple plasma exchange therapy requires special facilities and equipment, and has disadvantages such as elderly patients and patients with circulatory failure that cannot be performed.
- intravenous immunoglobulin therapy is carefully administered to patients with a history of shock or hypersensitivity. In view of the above, a therapeutic agent that is easy to use and has few side effects is desired in the medical field.
- Metabolic peripheral neuropathy is caused by various metabolic abnormalities, and there are various causes such as diabetes, uremia, collagen disease, vitamin deficiency, hypothyroidism and the like.
- diabetes is the most frequent cause of peripheral neuropathy, and the number of patients is expected to increase further in the future.
- One of the manifestation mechanisms of diabetic peripheral neuropathy is an increase in the polyol pathway that metabolizes glucose to sorbitol, and it is considered that nerve cells are damaged by excessively accumulated sorbitol (Non-patent Document 13).
- aldose reductase inhibitors related to the polyol pathway are effective for diabetic peripheral neuropathy, but Epalrestat is only approved in Japan and patients with relatively mild pathology In many cases, it is not effective in severe patients or patients with a long history of illness (Non-patent Document 14).
- pregabalin and duloxetine are used for pain due to diabetic peripheral neuropathy, but since it is not a drug for peripheral neuropathy, a new drug that has a remarkable effect on diabetic peripheral neuropathy is desired. ing.
- Inherited hereditary peripheral neuropathies include Charcot-Marie-Tooth disease, familial amyloid polyneuropathy, hereditary pressure-sensitive neuropathy, hereditary neuralgia muscular atrophy, and the like. The most representative is Charcot-Marie-Tooth disease. At least 50 genes are known to be involved in Charcot-Marie-Tooth disease. There are mutations in genes involved in myelination and formation / maintenance of nerve cells, and there are many variants. Usually, motor and sensory nerves are impaired, and movement disorders are prominent in many cases. Physical therapy and occupational therapy for maintaining muscle strength may be performed clinically, but there are currently no effective treatments or drugs for hereditary peripheral neuropathy, including Charcot-Marie-Tooth disease (Non-patent Document 15) .
- peripheral neuropathy of various causes there are patients who do not have an effective drug or patients who are ineffective even if there is a drug, and therefore, the creation of a new drug for peripheral neuropathy is expected.
- Non-patent Document 16 drugs that are effective for peripheral neuropathy in general are very useful, but no such drugs currently exist. Nevertheless, it is possible to create drugs that are effective for peripheral neuropathy in general.
- peripheral neuropathy is classified into many types and various clinical symptoms. However, the fact that peripheral neuropathy develops when the cells that make up peripheral nerves are damaged is common regardless of the cause. Because.
- Non-patent Document 17 a drug based on a neurotrophic factor which is an in vivo molecule related to survival, proliferation or maintenance of nerve cells is expected to be widely effective against peripheral neuropathy.
- Non-patent Document 18 drugs based on neurotrophic factors have not been shown to be effective. 19
- Patent Document 1 discloses that cyclic amine derivatives have analgesic activity, but there is no report suggesting an effect on peripheral neuropathy.
- An object of the present invention is to provide a therapeutic or preventive agent for peripheral neuropathy.
- the present invention provides a therapeutic or preventive agent for peripheral neuropathy, which contains a cyclic amine derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.
- a cyclic amine derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.
- A represents a group represented by the general formula (IIa), (IIb) or (IIc);
- R 1 represents a methyl group or an ethyl group which may be substituted with a halogen atom
- R 2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, and each R 3 independently represents: Represents a methyl group or an ethyl group, and n represents 1 or 2.
- A is preferably a group represented by the general formula (IIa), and in this case, R 1 is a methyl group or an ethyl group which may be substituted with a fluorine atom. More preferably, R 1 is more preferably a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.
- A is preferably a group represented by the general formula (IIb) or (IIc).
- R 1 is a methyl group optionally substituted with a fluorine atom, More preferably, it is an ethyl group, and R 1 is more preferably a methyl group, an ethyl group, a difluoromethyl group, or a 2,2,2-trifluoroethyl group.
- A is a group represented by the general formula (IIa), and the stereochemistry of the asymmetric carbon marked with * is preferably S configuration, in which R 1 is More preferably, it is a methyl group or an ethyl group which may be substituted with a fluorine atom, and R 1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group. Further preferred.
- the present invention also provides a peripheral neuropathy containing the cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof, a pharmacologically acceptable excipient, and the like.
- Pharmaceutical compositions for treatment or prevention are provided.
- the present invention also provides a cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof for use in the treatment or prevention of peripheral neuropathy.
- the present invention also provides use of the cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof for treating or preventing peripheral neuropathy.
- the present invention also provides use of the cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof in the manufacture of a medicament for treating or preventing peripheral neuropathy.
- the present invention also relates to a method for treating or preventing peripheral neuropathy, wherein a therapeutically effective amount of the cyclic amine derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof is given to a patient in need of treatment.
- a method comprising administering a salt to be prepared.
- the peripheral neuropathy is a drug-induced peripheral neuropathy, autoimmune peripheral neuropathy, metabolic peripheral neuropathy, hereditary peripheral neuropathy, vasculitic peripheral neuropathy, toxic peripheral
- a drug-induced peripheral neuropathy, autoimmune peripheral neuropathy, metabolic peripheral neuropathy, hereditary peripheral neuropathy, vasculitic peripheral neuropathy, toxic peripheral Preferably neurological disorder, infectious peripheral neuropathy, or peripheral neuropathy associated with malignant tumor, drug-induced peripheral neuropathy, autoimmune peripheral neuropathy, metabolic peripheral neuropathy, or inherited peripheral neuropathy More preferably, it is a drug-induced peripheral neuropathy, an autoimmune peripheral neuropathy, or a metabolic peripheral neuropathy.
- the pharmaceutical peripheral neuropathy is preferably an anticancer drug-induced peripheral neuropathy.
- the above autoimmune peripheral neuropathies include Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuritis (CIDP), multifocal motor neuropathy (MMN), and neuropathy associated with abnormal proteinemia. It is preferably at least one selected from obstacles (PPN).
- the metabolic peripheral neuropathy is preferably a diabetic peripheral neuropathy.
- the hereditary peripheral neuropathy is preferably Charcot-Marie-Tooth disease.
- the cyclic amine derivative of the present invention or a pharmacologically acceptable salt thereof can treat or prevent peripheral neuropathy.
- the peripheral neuropathy is, for example, a drug-related peripheral neuropathy, an autoimmune peripheral neuropathy, or a metabolic peripheral neuropathy.
- the above-mentioned drug-induced peripheral neuropathy is in particular an anticancer drug-induced peripheral neuropathy.
- the above-mentioned autoimmune peripheral neuropathy is particularly associated with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuritis (CIDP), multifocal motor neuropathy (MMN), and dysproteinemia. It is at least one selected from accompanying neuropathy (PPN).
- Said metabolic peripheral neuropathy is in particular a diabetic peripheral neuropathy.
- Said hereditary peripheral neuropathy is in particular Charcot-Marie-Tooth disease.
- FIG. 5 shows the effect of Compound 1 on the clinical score of a rat experimental autoimmune neuritis model.
- FIG. 5 shows the effect of Compound 1 on weight loss in a rat experimental autoimmune neuritis model.
- FIG. 2 shows the effect of Compound 1 on mechanical allodynia in a rat experimental autoimmune neuritis model.
- a cyclic amine derivative according to an embodiment of the present invention is characterized by being represented by the following general formula (I).
- the carbon marked with * is an asymmetric carbon
- A represents a group represented by the general formula (IIa), (IIb) or (IIc)
- R 1 represents a methyl group or an ethyl group which may be substituted with a halogen atom
- R 2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms
- each R 3 independently represents: Represents a methyl group or an ethyl group
- n represents 1 or 2.
- A is preferably a group represented by the general formula (IIa), and R 1 is preferably a methyl group or an ethyl group which may be substituted with a fluorine atom, More preferably, R 1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.
- A is preferably a group represented by the general formula (IIb) or (IIc), and R 1 may be a methyl group or an ethyl group optionally substituted with a fluorine atom. And R 1 is more preferably a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.
- A is preferably a group represented by the general formula (IIa), and the stereochemistry of the asymmetric carbon marked with * is preferably S configuration, in which case R 1 Is preferably a methyl group or an ethyl group optionally substituted by a fluorine atom, and R 1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group Is more preferable.
- A is a group represented by the general formula (IIa), and R 1 is a methyl group, an ethyl group, a difluoromethyl group, or a 2,2,2-trifluoroethyl group.
- R 2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, and R 3 each independently represents a methyl group or an ethyl group.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIa), R 1 represents a methyl group or a 2,2,2-trifluoroethyl group, and R 2 represents A hydrogen atom or an alkylcarbonyl group having 2 carbon atoms is represented, and R 3 represents a methyl group.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIb), R 1 represents a methyl group or an ethyl group which may be substituted with a fluorine atom, and R 2 Represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, R 3 independently represents a methyl group or an ethyl group, and n represents 1 or 2.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIb), and R 1 is a methyl group, an ethyl group, a difluoromethyl group, or a 2,2,2-trifluoroethyl group.
- R 2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms
- R 3 independently represents a methyl group or an ethyl group
- n represents 1 or 2.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIb), R 1 represents a methyl group or a 2,2,2-trifluoroethyl group, and R 2 represents Represents a hydrogen atom or an alkylcarbonyl group having 2 carbon atoms, R 3 represents a methyl group, and n represents 1 or 2;
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIc), R 1 represents a methyl group or an ethyl group which may be substituted with a fluorine atom, and R 2 Represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, and R 3 represents a methyl group or an ethyl group.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIc), and R 1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.
- R 2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, and R 3 represents a methyl group or an ethyl group.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- A is a group represented by the general formula (IIc), R 1 represents a methyl group or a 2,2,2-trifluoroethyl group, and R 2 represents A hydrogen atom or an alkylcarbonyl group having 2 carbon atoms is represented, and R 3 represents a methyl group.
- the stereochemistry of the asymmetric carbon marked with * is preferably S configuration.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the methyl group or ethyl group optionally substituted with a halogen atom means a methyl group or an ethyl group in which each hydrogen atom may be independently substituted with the above halogen atom. Examples thereof include a methyl group or an ethyl group, a difluoromethyl group, a 2-fluoroethyl group, a 2-chloroethyl group, a 2,2-difluoroethyl group, or a 2,2,2-trifluoroethyl group.
- C2-C5 alkylcarbonyl group means a group in which a linear, branched or cyclic saturated hydrocarbon group having 1 to 4 carbon atoms is bonded to a carbonyl group, such as an acetyl group, Examples thereof include an n-propionyl group, an n-butyryl group, an isobutyryl group, and a valeryl group.
- cyclic amine derivative (I) Preferred specific examples of the cyclic amine derivative represented by the above general formula (I) (hereinafter referred to as cyclic amine derivative (I)) are shown in Table 1-1 and Table 1-2, but the present invention is not limited thereto. is not.
- cyclic amine derivative (I) when isomers, such as an enantiomer and a stereoisomer, exist in cyclic amine derivative (I), any one isomer and mixtures thereof are included in cyclic amine derivative (I).
- cyclic amine derivative (I) contains isomers, such as an enantiomer and a stereoisomer, any one isomer and mixtures thereof are also contained in cyclic amine derivative (I).
- isomers due to conformation may be generated, and such isomers and mixtures thereof are also included in the cyclic amine derivative (I).
- the target isomer can be obtained by a known method or a method analogous thereto. For example, when the enantiomer exists in the cyclic amine derivative (I), the enantiomer separated from the cyclic amine derivative (I) is also included in the cyclic amine derivative (I).
- the target enantiomer is a known means (for example, an optically active synthetic intermediate is used, or a known method or an equivalent method (for example, optical resolution) is used for a racemic mixture of the final product) Can be obtained.
- the present invention also includes a prodrug of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof.
- the prodrug of the cyclic amine derivative (I) is a compound that is enzymatically or chemically converted into the cyclic amine derivative (I) in vivo.
- the active body of the prodrug of the cyclic amine derivative (I) is the cyclic amine derivative (I), but the prodrug itself of the cyclic amine derivative (I) may have activity.
- Examples of the prodrug of the cyclic amine derivative (I) include compounds in which the hydroxyl group of the cyclic amine derivative (I) is alkylated, phosphorylated or borated. These compounds can be synthesized from the cyclic amine derivative (I) according to a known method.
- prodrugs of the cyclic amine derivative (I) are known in the literature ("Development of Pharmaceuticals", Hirokawa Shoten, 1990, Vol. 7, p.163-198 and Progress in Medicine, Vol. 5, 1985, p. .2157 to 2161) may be converted into the cyclic amine derivative (I).
- the cyclic amine derivative (I) may be labeled with an isotope.
- Examples of the labeled isotope include 2 H, 3 H, 13 C, 14 C, 15 N, 15 O, 18 O and / or Or 125 I is mentioned.
- Examples of the pharmacologically acceptable salt of the cyclic amine derivative (I) include inorganic acid salts such as hydrochloride, sulfate, phosphate and hydrobromide, oxalate, malonate, Citrate, fumarate, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, salicylate, xinafoate, pamo And organic acid salts such as acid salts, ascorbates, adipates, methanesulfonates, p-toluenesulfonates and cinnamates. In addition, these salts may form hydrates, solvates or crystalline polymorphs.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof can be synthesized, for example, according to a method described in known literature (International Publication No. 2016/136944).
- Peripheral nerves include sensory nerves, motor nerves and autonomic nerves.
- Peripheral neuropathy is caused by damage to at least one of the nerve cells and myelin sheath (Schwann cell) constituting the peripheral nerve.
- Peripheral neuropathies are not limited to those listed below, but include, for example, drug-induced peripheral neuropathy, autoimmune peripheral neuropathy, metabolic peripheral neuropathy, hereditary peripheral neuropathy, vasculitic peripheral Examples include neuropathy, toxic peripheral neuropathy, infectious peripheral neuropathy, and peripheral neuropathy associated with malignant tumors.
- peripheral neuropathy is not limited to those listed below.
- the injured nerve is a sensory nerve, numbness of the limbs (abnormal sensation), illusion, dullness, pain
- the nerve to be injured is a motor nerve, such as muscle weakness / atrophy, flaccid paralysis, and decrease / disappearance of deep tendon reflex, etc.
- the injured nerve is an autonomic nerve Examples include constipation, abdominal pain, sweating disorder, dysuria, and orthostatic hypotension.
- Examples of drug-induced peripheral neuropathy include peripheral neuropathy caused by anticancer drugs, peripheral neuropathy caused by antiviral drugs, peripheral neuropathy caused by antibacterial drugs, peripheral neuropathy caused by antituberculosis drugs, peripheral neuropathy caused by antiarrhythmic drugs, Examples include peripheral neuropathy caused by hyperlipidemic drugs, peripheral neuropathy caused by immunosuppressive drugs, peripheral neuropathy caused by gout drugs, and peripheral neuropathy caused by other drugs.
- Anticancer agents include, for example, nucleic acid metabolism inhibitors, microtubule polymerization or depolymerization inhibitors, hormone antagonists, intracellular signal transduction inhibitors, malignant tumor-specific molecular targeted drugs, nonspecific immunostimulators, etc. Can be mentioned.
- nucleic acid metabolism inhibitor examples include alkylating agents, antitumor antibiotics, topoisomerase inhibitors, platinum preparations, pyrimidine metabolism inhibitors, purine metabolism inhibitors, folic acid synthesis inhibitors, and the like.
- microtubule polymerization or depolymerization inhibitor examples include vinca alkaloid anticancer agents and taxane anticancer agents.
- hormone antagonists include antiestrogens and antiandrogens.
- intracellular signal transduction inhibitors examples include proteosome inhibitors and cereblon inhibitors.
- malignant tumor-specific molecular targeting drugs include tyrosine kinase inhibitors, antibody preparations, arsenic preparations and the like.
- non-specific immunostimulants include streptococcal preparations and potato bamboo polysaccharide preparations.
- nucleic acid metabolism inhibitors include oxaliplatin, cisplatin, carboplatin, nedaplatin, cytarabine, nelarabine, etoposide, teniposide, and the like.
- polymerization or depolymerization inhibitor examples include paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vinorelbine, vindesine, eribulin, vinflunine, epothilone, ixabepilone and the like, and intracellular signal transduction inhibitors include, for example, bortezomib and carfilzomib
- intracellular signal transduction inhibitors include, for example, bortezomib and carfilzomib
- malignant tumor-specific molecular targeting drug examples include brentuximab vedotin, trastuzumab emtansine, thalidomide, pomalidomide, lenalidomide, and the like.
- Antiviral drugs are not limited to those listed below, but include, for example, efavirenz, emtricitabine, emtricitabine, tenofovir disoproxil, saquinavir, sanylvudine, zalcitabine, didanosine, stavudine, zidopudine, darunavir, delavirdine mesyl Acid salts, nevirapine, tenofovir fumarate disoproxil, foscalnet sodium hydrate, lamivudine, lamivudine / abacavir sulfate, ritonavir, ribavirin, lopinavir / ritonavir, atazanavir, indinavir and the like.
- Antibacterial agents include, but are not limited to, for example, chloramphenicol, nitrofurantoin, metronidazole, diphenylsulfone, ethambutol, fluoroquinolone (levofloxacin, ciprofloxacin, moxifloxax Syn, norfloxacin, ofloxacin, etc.).
- antituberculosis drugs examples include, but are not limited to, isoniazid and ethambutol.
- Antiarrhythmic drugs are not limited to those listed below, and examples include amiodarone and procainamide.
- antihyperlipidemic drugs are not limited to those listed below, and examples include pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin and the like.
- immunosuppressive drugs are not limited to those listed below, but examples include tacrolimus, cyclosporine, mycophenolate mofetil, leflunomide, chloroquine, interferon ⁇ , and gold preparations.
- drugs include, but are not limited to, for example, gout treatment colchicine or allopurinol, antiepileptic phenytoin, anesthetic nitrous oxide, vitamin pyridoxine, anti-alcohol Disulfiram, hydralazine as a hypotensive drug, and the like.
- -Drugs that cause drug-induced peripheral neuropathy include not only those found so far based on the above classification, but also those that will be found in the future.
- autoimmune peripheral neuropathy examples include, but are not limited to, the following: Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuritis, multifocal motor neuropathy and abnormal proteinemia Neuropathy associated with the disease.
- subtypes included in Guillain-Barre syndrome include acute inflammatory demyelinating neuritis, acute motor axon type neuritis, acute motor sensory axon type neuritis, and Fisher syndrome.
- Metabolic peripheral neuropathy is not limited to those listed below, for example, diabetic peripheral neuropathy, uremic peripheral neuropathy, collagenous peripheral neuropathy, vitamin deficient peripheral neuropathy, Examples include hypothyroid peripheral neuropathy.
- Hereditary peripheral neuropathies are not limited to those listed below, but include, for example, Charcot-Marie-Tooth disease, familial amyloid polyneuropathy, hereditary pressure fragile neuropathy, hereditary neuralgia muscle atrophy Symptoms and the like.
- Whether the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof has an inhibitory effect on peripheral nerve cell damage can be evaluated using rat dorsal root ganglion-derived cell lines. Specifically, cell activity reduction is induced by treating a rat dorsal root ganglion-derived established neuronal cell with a cytotoxic substance, and its inhibitory effect on the cell activity reduction is evaluated.
- Whether the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof has a myelination promoting action can be evaluated using rat dorsal root ganglion nerve / Schwann cell co-culture. Specifically, rat dorsal root ganglion neurons and Schwann cells are cultured together to induce myelination by ascorbic acid treatment and evaluate whether the myelination is promoted.
- cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is effective for the treatment or prevention of drug-induced peripheral neuropathy, particularly anticancer drug-induced peripheral neuropathy, It can be evaluated using a peripheral neuropathy model induced by a cancer drug (Hoeke et al., ILAR Journal, 2014, Vol. 54, p.273-281).
- cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is effective for treating or preventing autoimmune peripheral neuropathy is based on an experimental autoimmune neuritis (EAN) model. (Soliven, ILAR Journal, 1994, Vol. 54, p.282-290).
- the effectiveness of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof for the treatment or prevention of metabolic peripheral neuropathy, particularly diabetic peripheral neuropathy, can be evaluated using a streptozotocin-induced diabetes model ( O'Brien et al., ILAR Journal, 2014, Vol. 54, pp. 259-272).
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is an excellent peripheral compound for mammals (eg, mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey or human), particularly humans. It can be used as a pharmaceutical useful for the treatment or prevention of neuropathy.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is used as a medicine
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is incorporated as it is or a pharmaceutically acceptable carrier.
- it can be administered orally or parenterally.
- Examples of dosage forms for oral administration of a pharmaceutical containing the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof as an active ingredient include tablets (including sugar-coated tablets and film-coated tablets), pills, Examples include granules, powders, capsules (including soft capsules and microcapsules), syrups, emulsions, and suspensions.
- Examples of dosage forms for parenteral administration of a pharmaceutical containing the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof as an active ingredient include, for example, injections, infusions, infusions, and suppositories. And a coating agent or a patch.
- a suitable base for example, a polymer of butyric acid, a polymer of glycolic acid, a copolymer of butyric acid-glycolic acid, a mixture of a polymer of butyric acid and a polymer of glycolic acid, or a polyglycerol fatty acid ester
- a suitable base for example, a polymer of butyric acid, a polymer of glycolic acid, a copolymer of butyric acid-glycolic acid, a mixture of a polymer of butyric acid and a polymer of glycolic acid, or a polyglycerol fatty acid ester
- the preparation of the above dosage form can be performed according to a known production method generally used in the pharmaceutical field. In this case, if necessary, it is produced by containing excipients, binders, lubricants, disintegrants, sweeteners, surfactants, suspending agents, emulsifiers and the like generally used in the pharmaceutical field. be able to.
- Tablets can be prepared, for example, by containing an excipient, a binder, a disintegrant, or a lubricant. Pills and granules can be prepared, for example, by containing an excipient, a binder or a disintegrant. Moreover, powders and capsules can be prepared, for example, by containing an excipient.
- the syrup preparation can be prepared, for example, by adding a sweetener.
- the emulsion or suspension can be prepared, for example, by containing a surfactant, suspending agent or emulsifier.
- excipient examples include lactose, glucose, starch, sucrose, microcrystalline cellulose, licorice powder, mannitol, sodium bicarbonate, calcium phosphate or calcium sulfate.
- binder examples include starch paste, gum arabic solution, gelatin solution, tragacanth solution, carboxymethyl cellulose solution, sodium alginate solution, and glycerin.
- disintegrant examples include starch and calcium carbonate.
- Examples of the lubricant include magnesium stearate, stearic acid, calcium stearate, and purified talc.
- sweetener examples include glucose, fructose, invert sugar, sorbitol, xylitol, glycerin and simple syrup.
- surfactant examples include sodium lauryl sulfate, polysorbate 80, sorbitan monofatty acid ester, and polyoxyl 40 stearate.
- suspending agent examples include gum arabic, sodium alginate, sodium carboxymethyl cellulose, methyl cellulose, and bentonite.
- emulsifier examples include gum arabic, tragacanth, gelatin, and polysorbate 80.
- a pharmaceutical containing the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof as an active ingredient is prepared in the above-mentioned dosage form, a colorant generally used in the pharmaceutical field, storage Agents, fragrances, flavoring agents, stabilizers, thickeners and the like can be added.
- the daily dose of the pharmaceutical containing the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof as an active ingredient varies depending on the patient's condition or body weight, the type of compound or the administration route, etc.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is divided into 1 to 3 times within the range of 1 to 1000 mg as an active ingredient amount.
- the body weight is 1 kg with the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof as the active ingredient amount. It is preferably administered by intravenous injection in the range of 0.01 to 100 mg per unit.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof may be used in combination with or in combination with other drugs in order to supplement or enhance the therapeutic or preventive effect, or to reduce the dose.
- it can be used in combination with a drug that relieves symptoms of peripheral neuropathy.
- Propan-1-one (hereinafter referred to as Compound 1) was synthesized according to a method described in a known document (International Publication No. 2016/136944).
- Example 1 Protective effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on cytotoxicity in rat dorsal root ganglion-derived cell lines: The protective effect of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof against cytotoxicity in rat dorsal root ganglion-derived neuronal cells was examined.
- Rat fetal dorsal root ganglion-derived cell line ND15 was cultured in DMEM medium containing 10% FBS. The next day, the cells were cultured for 8 days in a DMEM medium containing 10% FBS containing EC23 (10 ⁇ M, Reinner) and differentiated into neurons.
- Cytotoxicity was induced by exchanging with DMEM / F12 medium containing cisplatin (final concentration 50 ⁇ M) and culturing for 4 hours.
- Compound 1 was treated in the medium as in cisplatin (final concentration 0.5, 5 or 50 ⁇ M).
- the group composition was 6 groups: an untreated group, a compound 1 50 ⁇ M treated group, a cisplatin treated group, a cisplatin and compound 1 0.5 ⁇ M treated group, a cisplatin and compound 1 5 ⁇ M treated group, a cisplatin and compound 1 50 ⁇ M treated group.
- the medium was replaced with DMEM / F12 medium containing Alamar Blue (Invitrogen), and after culturing for 2 hours, absorbance at 570 nm and 595 nm was measured. Cell activity was calculated by the ratio of the absorbance at 570 nm to the absorbance at 595 nm, and the untreated group was defined as 100%.
- FIG. 1 The results of evaluating the effect of Compound 1 on cell activity are shown in FIG.
- shaft of FIG. 1 shows cell activity (%) (mean value +/- standard error; 6 cases for each group). From the left, the horizontal axis shows an untreated group, a compound 1 50 ⁇ M treated group, a cisplatin treated group, a cisplatin and compound 1 0.5 ⁇ M treated group, a cisplatin and compound 1 5 ⁇ M treated group, and a cisplatin and compound 1 50 ⁇ M treated group.
- Example 2 Repair effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on cytotoxicity in rat dorsal root ganglion-derived cell lines: The repair effect of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on cytotoxicity in rat dorsal root ganglion-derived cell lines was examined.
- cytotoxicity induced by cisplatin was induced on rat fetal dorsal root ganglion-derived cell line ND15, and the cell activity was measured.
- Compound 1 was treated for 24 hours after treatment with cisplatin for 24 hours (final concentration 0.5, 5 or 50 ⁇ M).
- the group composition was 6 groups: an untreated group, a compound 1 50 ⁇ M treated group, a cisplatin treated group, a cisplatin and compound 1 0.5 ⁇ M treated group, a cisplatin and compound 1 5 ⁇ M treated group, a cisplatin and compound 1 50 ⁇ M treated group.
- FIG. 1 The results of evaluating the effect of Compound 1 on cell activity are shown in FIG.
- shaft of FIG. 2 shows cell activity (%) (mean value +/- standard error; each group 6 examples). From the left, the horizontal axis shows an untreated group, a compound 1 50 ⁇ M treated group, a cisplatin treated group, a cisplatin and compound 1 0.5 ⁇ M treated group, a cisplatin and compound 1 5 ⁇ M treated group, and a cisplatin and compound 1 50 ⁇ M treated group.
- the dorsal root ganglion was removed from the fetus of a female SD rat on the 15th day of gestation, and cultured separately into nerve cells and Schwann progenitor cells (the first day of cell culture was defined as Day 1).
- the first day of cell culture was defined as Day 1.
- co-culture was started by adding Schwann progenitor cells to the neuronal cell culture medium.
- Myelination was induced by treatment with ascorbic acid on the 26th to 40th day (Day 26 to 40) from the first day of the start of cell culture (a total of 4 to 5 times according to the medium change of 2-3).
- Compound 1 In combination with ascorbic acid treatment, Compound 1 (final concentration 30 ⁇ M) dissolved in sterile distilled water was treated 4 to 5 times in total. As a control, sterile distilled water was treated instead of the Compound 1 solution. There were two groups, a sterile distilled water treatment group (vehicle treatment group) and a 30 ⁇ M compound 1 treatment group (compound 1 treatment group).
- the cells were washed with phosphate buffered saline on days 40 to 43 (Days 40 to 43) from the first day of cell culture, and then fixed with 4% paraformaldehyde / phosphate buffer. After methanol treatment and blocking, myelin marker protein Myelin Basic Protein (MBP) was fluorescently immunostained.
- MBP Myelin marker protein Myelin Basic Protein
- a fluorescent image of MBP was taken with a fluorescence microscope (DMI4000B, Leica), and the number of myelin sheath segments ( ⁇ 25 ⁇ m) was analyzed from the image.
- the analysis region (ROI) was defined as a region where the co-culture was divided into four, and MBP fibrous staining images were observed most frequently in each division.
- FIG. 3 The results of evaluating the effect of Compound 1 on myelination are shown in FIG.
- the vertical axis in FIG. 3 represents the number of myelin segments per ROI (mean ⁇ standard error; 8-12 cases in each group).
- the horizontal axis indicates the number of days for cell culture.
- a rat dorsal root ganglion nerve cell / Schwan cell co-culture was prepared in the same manner as in Example 3, and myelination was induced and Compound 1 was treated. There were two groups, a sterile distilled water treatment group (vehicle treatment group) and a 30 ⁇ M compound 1 treatment group (compound 1 treatment group).
- the coculture was dissolved in RIPA cell lysate, and the cell lysate was subjected to sodium dodecyl sulfate / polyacrylamide gel electrophoresis. Thereafter, the protein was transferred to a PVDF membrane, and an MBP band was detected by an antibody reaction. Image Lab software (BIO-RAD) was used for quantification of the detected bands.
- Results of evaluating the effect of Compound 1 on the expression level of MBP are shown in FIG.
- the vertical axis of FIG. 4 shows the relative expression level of MBP, where the average value of the Vehicle group is 1, (average value ⁇ standard error; 4 cases in each group).
- the horizontal axis shows the vehicle treatment group and the compound 1 treatment group from the left. “*” In the figure indicates a statistically significant difference (*: p ⁇ 0.05, Student's t test) as compared with the vehicle treatment group.
- Compound 1 treatment increased the number of myelin segments and increased the myelin marker protein MBP. That is, it was revealed that Compound 1 promotes myelination in rat dorsal root ganglion nerve / Schwan cell co-culture.
- Cyclic amine derivative (I) or pharmacologically acceptable salt thereof for allodynia (cold allodynia) for cold stimulation and allodynia (mechanical allodynia) for touch stimulation in rat oxaliplatin-induced peripheral neuropathy model Effects of repeated administration of: The effect of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on cold allodynia and mechanical allodynia caused by administration of oxaliplatin was examined.
- oxaliplatin-induced peripheral neuropathy model was prepared.
- 5% glucose solution (Otsuka Pharmaceutical Factory) was administered, and the first administration day was set as the 0th day of disease state induction.
- a solution containing Compound 1 (3 or 10 mg / kg) or a solvent thereof (water for injection; Otsuka Pharmaceutical Factory) is orally administered to rats twice daily for 18 days (the second administration is 1 8 hours after the first administration).
- the first administration was performed before the oxaliplatin administration on the 0th day after the induction of the disease state, and the first administration was performed after the evaluation on the allodynia evaluation day.
- the group composition is: sham induction-solvent administration group (Sham group), disease state induction-solvent administration group (Vehicle group), disease state induction-3 mg / kg compound 1 administration group (3 mg / kg compound 1 administration group), disease state induction-10 mg 4 groups of / kg Compound 1 administration group (10 mg / kg Compound 1 administration group).
- Drug efficacy evaluation for cold allodynia was performed before pathogenesis and on the 12th day (before the first administration of Compound 1).
- the efficacy against cold allodynia was evaluated by the Cold Plate test.
- a Cold Plate apparatus Ugo Basile was used for the test. Place the animal on a plate maintained at a constant temperature (8 ° C) and measure the escape latency until pain-related behavior (lifting, shaking, licking, standing, jumping) is confirmed. did. The cut off time was 180 seconds.
- the medicinal efficacy evaluation for mechanical allodynia was performed before the induction of the disease state and on the 18th day (before the first administration of Compound 1).
- the efficacy against mechanical allodynia was evaluated by the von Frey test.
- the test method was carried out using von Frey filament (North Coast Medical) according to the method described in known literature (Chaplan et al., Journal of Neuroscience Methods, 1994, Vol. 53, p.55-63).
- the reaction threshold was calculated.
- FIG. 5 shows the results of evaluating the effect of Compound 1 on cold allodynia.
- the vertical axis in FIG. 5 shows the escape latency in the Cold Plate test, and the higher the value, the better the cold allodynia (mean value ⁇ standard error; 10 cases in each group).
- the horizontal axis shows each administration group from the left before the induction of the disease state (in the figure, “Day 0 (before the induction of the disease state)”) and 12 days after the induction of the disease state (in the figure, “Day 12 (after the induction of the disease state)”).
- “#” In the figure indicates a statistically significant difference (#: p ⁇ 0.05, Student's t test) compared to the Sham group, and “*” in the figure indicates Vehicle. It shows that the difference is statistically significant (*: p ⁇ 0.025, multiple comparison of Williams, one-sided) compared with the group.
- FIG. 6 shows the results of evaluating the effect of Compound 1 on mechanical allodynia.
- the vertical axis of FIG. 6 shows the 50% response threshold in the von Frey test, and the higher the value, the better the mechanical allodynia (mean ⁇ standard error; 10 cases in each group).
- the horizontal axis shows each administration group from the left before the induction of the disease state (in the figure, “Day 0 (before the induction of the disease state)”) and 18 days after the induction of the disease state (in the figure, “Day 18 (after the induction of the disease state)”).
- “#” In the figure indicates a statistically significant difference (#: p ⁇ 0.05, Welch's t test) compared to the Sham group, and “*” in the figure indicates Vehicle. The difference is statistically significant (*: p ⁇ 0.025, Shirley-Williams multiple comparison, one-sided) compared with the group.
- Example 6 The therapeutic effect of a single administration of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on mechanical allodynia in a rat cisplatin-induced peripheral neuropathy model: The effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on mechanical allodynia caused by the administration of cisplatin was examined.
- Cisplatin-induced peripheral neuropathy is induced by intermittent administration of cisplatin (Wako Pure Chemical Industries) intraperitoneally twice a week (1 or 2 mg / kg) for 5 weeks in SD rats (6 weeks old, male; Charles River, Japan) A model was created. Cisplatin was dissolved in physiological saline and adjusted to 10 mg / mL for administration. As a control (sham induction), physiological saline was administered. The first administration day was defined as the first day of disease induction.
- a solution containing Compound 1 (10 mg / kg) or a solvent thereof (water for injection) was orally administered to rats.
- the medicinal efficacy evaluation for mechanical allodynia was evaluated in the same manner as in Example 5, and was performed before administration of Compound 1 on Day 34 and 2 hours after administration.
- FIG. 7 shows the results of evaluating the effect of Compound 1 on mechanical allodynia.
- the vertical axis in FIG. 7 shows the 50% reaction threshold in the von Frey test, and the higher the value, the better the mechanical allodynia (mean ⁇ standard error; 4-6 cases in each group).
- the horizontal axis represents each administration group from the left before administration of Compound 1 (in the figure, “Day 34 (before administration)”) and 2 hours after administration of the compound (in the figure, “Day 34 (2 hours after administration)”).
- “#” In the figure indicates a statistically significant difference (#: p ⁇ 0.05, Student's t test) compared to the Sham group, and “*” in the figure indicates Vehicle. The difference is statistically significant (*: p ⁇ 0.05, Student's t-test) compared to the group.
- Example 7 Effect of single administration of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on mechanical allodynia in rat paclitaxel-induced peripheral neuropathy model: The effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on mechanical allodynia caused by the administration of paclitaxel was examined.
- Paclitaxel-induced peripheral neuropathy model was prepared by intraperitoneally administering paclitaxel (4 mg / kg, ChromaDex) 4 times every other day to SD rats (6 weeks old, male; Charles River, Japan). Paclitaxel was dissolved in Cremophor EL (Nacalai Tesque) and ethanol (Wako Pure Chemicals) mixed at 1: 1 to prepare 6 mg / mL, and diluted with physiological saline to 4 mg / mL and administered. The first administration day was defined as Day 0 of pathological induction.
- the medicinal efficacy evaluation for mechanical allodynia was evaluated in the same manner as in Example 5, and was performed before the induction of the disease state and on the 14th day (3 hours after administration of Compound 1).
- FIG. 8 shows the result of evaluation of the effect of Compound 1 on mechanical allodynia.
- the vertical axis in FIG. 8 indicates the 50% response threshold in the von Frey test, and the higher the value, the better the mechanical allodynia (mean ⁇ standard error; 8 cases in each group).
- the horizontal axis shows each administration group from the left before induction of the disease state and 3 hours after administration of Compound 1 on the 14th day of induction (in the figure, “Day 14 (3 hours after administration)”). “*” In the figure indicates a statistically significant difference (*: p ⁇ 0.05, Student's t-test, two-sided) compared to the Vehicle group.
- the medicinal efficacy evaluation for mechanical allodynia was evaluated by the same method as in Example 5, and was performed before pathogenesis and on the 15th day after pathogenesis (3 hours after administration of Compound 1).
- FIG. 9 The results of evaluating the effect of Compound 1 on mechanical allodynia are shown in FIG.
- the vertical axis in FIG. 9 shows the 50% response threshold in the von Frey test, and the higher the value, the better the mechanical allodynia (mean ⁇ standard error; 8 cases in each group).
- the horizontal axis shows each administration group from the left before induction of the disease state and 3 hours after administration of Compound 1 on the 15th day of induction of the disease (“Day 15 (3 hours after administration)” in the figure). “*” In the figure indicates a statistically significant difference (*: p ⁇ 0.05, Student's t-test, two-sided) compared to the Vehicle group.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof has a remarkable inhibitory effect on peripheral neuropathy induced by drugs, particularly anticancer agents.
- Example 9 Effect of cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on an experimental autoimmune neuritis (EAN) model in rats: The inhibitory effect of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on the rat EAN model was examined.
- EAN model rat The preparation method of EAN model rat is shown.
- Peripheral myelin protein P2 partial peptide P2 (57-81) peptide (synthesized at Toray Research Center) was dissolved in physiological saline (Otsuka Pharmaceutical Factory) to prepare 2 mg / mL, and 2 mg / mL containing Mycobacterium tuberculosis H37Ra
- An equal volume of mL complete Freund's adjuvant (Difco Laboratories) was mixed to prepare an emulsion peptide administration solution.
- An EAN model was prepared by administering 200 ⁇ L of peptide administration solution subcutaneously to the ridge of Lewis rats (6-7 weeks old, male; Charles River, Japan) under anesthesia. The day of peptide administration was defined as day 0 of disease induction.
- Compound 1 (20 mg / kg) was dissolved in distilled water (Otsuka Pharmaceutical Factory) and orally administered to the EAN model twice a day (administration started from the 10th day of pathogenesis).
- distilled water was orally administered to the EAN model.
- the group composition was two groups, a solvent administration group (vehicle group) and a compound 1 administration group.
- the sciatic nerve and the tibial nerve were isolated on the 17th day after the induction of the pathological condition and immersed in a 10% neutral buffered formalin solution. After slicing, hematoxylin and eosin staining, Kluber-Barrera staining (double staining of Luxor Fast Blue staining and Nissl staining) and immunostaining (Iba1, CD3, NFP and MBP) were performed. The specimens were observed with an optical microscope to evaluate the presence of T cell and macrophage infiltration, myelin sheath and axon degeneration.
- FIG. 10 shows the results of evaluating the effect of Compound 1 on the clinical score.
- the increase in clinical score was suppressed as compared with the Vehicle group.
- FIG. 11 The results of evaluating the effect of Compound 1 on weight loss are shown in FIG.
- the vertical axis in FIG. 11 shows the weight of the rat (mean value ⁇ standard error, 6 to 7 cases in each group). Weight loss occurred in the Vehicle group, but no weight loss occurred in the 20 mg / kg Compound 1 administration group.
- Table 2 shows the number of individuals showing histological changes in the sciatic nerve and tibial nerve (3 cases in each group).
- Table 2 shows the number of individuals showing histological changes in the sciatic nerve and tibial nerve (3 cases in each group).
- In the Vehicle group infiltration of T cells and macrophages and degeneration of myelin sheath and axon were observed, but were hardly observed in the 20 mg / kg Compound 1 administration group.
- Example 10 Effect of cyclic amine derivative (I) or pharmacologically acceptable salt thereof on mechanical allodynia in rat experimental autoimmune neuritis (EAN) model: The inhibitory effect of the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof on mechanical allodynia in the rat EAN model was examined.
- EAN model rats were prepared in the same manner as in Example 9.
- a pseudo-induced animal was provided in which physiological saline (Otsuka Pharmaceutical Factory) was administered instead of the peptide administration solution.
- the administration day of the peptide administration solution or physiological saline was defined as the 0th day of pathological induction.
- Compound 1 (5 or 10 mg / kg) or a solvent thereof (water for injection) was orally administered to rats.
- the group composition is: sham induction-solvent administration group (Sham group), disease state induction-solvent administration group (Vehicle group), disease state induction-5 mg / kg compound 1 administration group (5 mg / kg compound 1 administration group), disease state induction-10 mg / Kg Compound 1 administration group (10 mg / kg Compound 1 administration group)
- the medicinal efficacy evaluation for mechanical allodynia was evaluated in the same manner as in Example 5, and was performed 3 hours after administration of Compound 1 on the 14th day of pathogenesis.
- FIG. 12 shows the results of evaluating the effect of Compound 1 on mechanical allodynia.
- the vertical axis in FIG. 12 shows the 50% response threshold in the von Frey test, and the higher the value, the better the mechanical allodynia (mean ⁇ standard error, 4-10 cases in each group).
- “#” In the figure indicates a statistically significant difference (#: p ⁇ 0.05, Student's t test) compared to the Sham group, and “*” in the figure indicates the Vehicle group. The difference is statistically significant (*: p ⁇ 0.025, Williams multiple comparison, one-sided).
- Streptozotocin-induced diabetes model was prepared by administering streptozotocin (50 mg / kg, Sigma-Aldrich) into SD rats (6 weeks old, male; Charles River, Japan) via tail vein. Streptozotocin was dissolved in citrate buffer and adjusted to 25 mg / mL for administration. In addition, non-pathologically induced animals were prepared in which no streptozotocin solution was administered. The first administration day was defined as the first day of disease induction.
- a solution containing Compound 1 (3 or 10 mg / kg) or a solvent thereof (water for injection) was orally administered to rats twice a day for 28 days from the 14th day of pathogenesis.
- Group composition is: pathological non-induction-solvent administration group (Normal group), pathological induction-solvent administration group (Vehicle group), pathological induction- 3 mg / kg compound 1 administration group (3 mg / kg compound 1 administration group), disease state induction- There were 4 groups of 10 mg / kg Compound 1 administration group (10 mg / kg Compound 1 administration group).
- the nerve conduction velocity was measured for 3 days from the day after the last administration.
- Two single-needle electrodes (A, B) are inserted into the thigh and brought into contact with the sciatic nerve, and one single-needle electrode (C) is inserted into the lower end of the gastrocnemius (Achilles tendon) and led to the toes.
- the electrode for was installed.
- Stimulus transmission time was analyzed in the respective derived waveforms obtained from the electrodes of the footpad, with the stimuli between AB and BC as distal and proximal stimuli, respectively.
- the nerve conduction velocity was calculated based on the difference in the transmission time between the distal stimulus and the proximal stimulus and the distance between the electrodes.
- FIG. 13 shows the results of evaluating the effect of Compound 1 on the decrease in nerve conduction velocity.
- the vertical axis in FIG. 13 represents nerve conduction velocity (mean value ⁇ standard error; 5 to 6 cases in each group).
- “#” In the figure indicates a statistically significant difference (#: p ⁇ 0.05, Student's t test) compared to the Normal group, and “*” in the figure indicates Vehicle. It shows that the difference is statistically significant (*: p ⁇ 0.025, multiple comparison of Williams, one-sided) compared with the group.
- Streptozotocin-induced diabetes model was prepared by administering streptozotocin (50 mg / kg, Sigma-Aldrich) into SD rats (6 weeks old, male; Charles River, Japan) via tail vein. Streptozotocin was dissolved in physiological saline (Otsuka Pharmaceutical Factory) and adjusted to 25 mg / mL for administration. In addition, a mock induced animal was provided in which physiological saline was administered instead of the streptozotocin solution. The first administration day was defined as Day 0 of pathological induction.
- the group composition is: sham induction-solvent administration group (Sham group), disease state induction-solvent administration group (Vehicle group), disease state induction-10 mg / kg compound 1 administration group (3 mg / kg compound 1 administration group), disease state induction-30 mg 4 groups of / kg Compound 1 administration group (10 mg / kg Compound 1 administration group).
- the medicinal efficacy evaluation for mechanical allodynia was evaluated in the same manner as in Example 5, and was performed 3 hours after administration of Compound 1 on the 28th day of pathogenesis.
- FIG. 14 shows the results of evaluating the effect of Compound 1 on mechanical allodynia.
- shaft of FIG. 14 shows the 50% reaction threshold value in von Frey test, and it shows that mechanical allodynia is improved, so that a numerical value is high (average value +/- standard error; each group 8 examples).
- “*” In the figure indicates a statistically significant difference (*: p ⁇ 0.025, Shirley-Williams multiple comparison, one-sided) as compared with the Vehicle group.
- the cyclic amine derivative (I) or a pharmacologically acceptable salt thereof is effective for metabolic peripheral neuropathy, particularly diabetic peripheral neuropathy.
- the cyclic amine derivative of the present invention or a pharmacologically acceptable salt thereof has a protective / repairing effect on peripheral nerve cells and a myelination promoting action, and remarkably suppresses symptoms of various peripheral neuropathies. Therefore, it can be used as a therapeutic or prophylactic agent for peripheral neuropathy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
[式中、*を付した炭素は不斉炭素であり、Aは、一般式(IIa)、(IIb)又は(IIc)で示される基を表し、
[式中、
*を付した炭素は不斉炭素であり、Aは、一般式(IIa)、(IIb)又は(IIc)で示される基を表し、
環状アミン誘導体(I)又はその薬理学的に許容される塩のラット後根神経節由来株化神経細胞における細胞傷害に対する保護効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラット後根神経節由来株化神経細胞における細胞傷害に対する修復効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラット後根神経節細胞・シュワン細胞共培養の髄鞘形成に対する促進効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラット後根神経節細胞・シュワン細胞共培養におけるMBPの発現量に対する効果を検討した。
オキサリプラチンの投与によって発症する冷的アロディニア及び機械的アロディニアに対する環状アミン誘導体(I)又はその薬理学的に許容される塩の効果を検討した。
シスプラチンの投与によって発症する機械的アロディニアに対する環状アミン誘導体(I)又はその薬理学的に許容される塩の効果を検討した。
パクリタキセルの投与によって発症する機械的アロディニアに対する環状アミン誘導体(I)又はその薬理学的に許容される塩の効果を検討した。
ボルテゾミブの投与によって発症する機械的アロディニアに対する環状アミン誘導体(I)又はその薬理学的に許容される塩の治療効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラットEANモデルに対する抑制効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラットEANモデルの機械的アロディニアに対する抑制効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラットストレプトゾトシン誘発糖尿病モデルの機械的アロディニアに対する抑制効果を検討した。
環状アミン誘導体(I)又はその薬理学的に許容される塩のラットストレプトゾトシン誘発糖尿病モデルの機械的アロディニアに対する抑制効果を検討した。
Claims (34)
- Aは、一般式(IIa)で示される基である、請求項1記載の治療剤又は予防剤。
- Aは、一般式(IIb)又は(IIc)で示される基である、請求項1記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基であり、*を付した不斉炭素の立体化学が、S配置である、請求項1記載の治療剤又は予防剤。
- R1は、フッ素原子で置換されていてもよい、メチル基又はエチル基である、請求項1~4のいずれか一項記載の治療剤又は予防剤。
- R1は、メチル基、エチル基、ジフルオロメチル基又は2,2,2-トリフルオロエチル基である、請求項1~4のいずれか一項記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基である、請求項7記載の治療剤又は予防剤。
- Aは、一般式(IIb)又は(IIc)で示される基である、請求項7記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基であり、*を付した不斉炭素の立体化学が、S配置である、請求項7記載の治療剤又は予防剤。
- R1は、フッ素原子で置換されていてもよい、メチル基又はエチル基である、請求項7~10のいずれか一項記載の治療剤又は予防剤。
- R1は、メチル基、エチル基、ジフルオロメチル基又は2,2,2-トリフルオロエチル基である、請求項7~10のいずれか一項記載の治療剤又は予防剤。
- 薬剤性末梢神経障害は、抗がん剤による末梢神経障害、抗ウイルス薬による末梢神経障害、抗菌薬による末梢神経障害、抗結核薬による末梢神経障害、抗不整脈薬による末梢神経障害、高脂血症治療薬による末梢神経障害、免疫抑制薬による末梢神経障害、痛風治療薬による末梢神経障害及びその他の薬剤による末梢神経障害等から選択される少なくとも1種である、請求項7~12のいずれか一項記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基である、請求項14記載の治療剤又は予防剤。
- Aは、一般式(IIb)又は(IIc)で示される基である、請求項14記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基であり、*を付した不斉炭素の立体化学が、S配置である、請求項14記載の治療剤又は予防剤。
- R1は、フッ素原子で置換されていてもよい、メチル基又はエチル基である、請求項14~17のいずれか一項記載の治療剤又は予防剤。
- R1は、メチル基、エチル基、ジフルオロメチル基又は2,2,2-トリフルオロエチル基である、請求項14~17のいずれか一項記載の治療剤又は予防剤。
- 自己免疫性末梢神経障害は、ギラン・バレー症候群、慢性炎症性脱髄性多発根神経炎、多巣性運動神経障害及び異常タンパク血症に伴う神経障害から選択される少なくとも1種である、請求項14~19のいずれか一項記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基である、請求項21記載の治療剤又は予防剤。
- Aは、一般式(IIb)又は(IIc)で示される基である、請求項21記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基であり、*を付した不斉炭素の立体化学が、S配置である、請求項21記載の治療剤又は予防剤。
- R1は、フッ素原子で置換されていてもよい、メチル基又はエチル基である、請求項21~24のいずれか一項記載の治療剤又は予防剤。
- R1は、メチル基、エチル基、ジフルオロメチル基又は2,2,2-トリフルオロエチル基である、請求項21~24のいずれか一項記載の治療剤又は予防剤。
- 代謝性末梢神経障害は、糖尿病性末梢神経障害、尿毒症性末梢神経障害、膠原病性末梢神経障害及びビタミン欠乏性末梢神経障害から選択される少なくとも1種である、請求項21~26のいずれか一項記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基である、請求項28記載の治療剤又は予防剤。
- Aは、一般式(IIb)又は(IIc)で示される基である、請求項28記載の治療剤又は予防剤。
- Aは、一般式(IIa)で示される基であり、*を付した不斉炭素の立体化学が、S配置である、請求項28記載の治療剤又は予防剤。
- R1は、フッ素原子で置換されていてもよい、メチル基又はエチル基である、請求項28~31のいずれか一項記載の治療剤又は予防剤。
- R1は、メチル基、エチル基、ジフルオロメチル基又は2,2,2-トリフルオロエチル基である、請求項28~31のいずれか一項記載の治療剤又は予防剤。
- 遺伝性末梢神経障害は、シャルコー・マリー・トゥース病、家族性アミロイド・ポリニューロパチー、遺伝性圧脆弱性ニューロパチー及び遺伝性神経痛性筋肉萎縮症から選択される少なくとも1種である、請求項28~33のいずれか一項記載の治療剤又は予防剤。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019010967A MX2019010967A (es) | 2017-03-31 | 2018-03-30 | Agente terapeutico o profilactico para neuropatias perifericas. |
JP2019510220A JP7163906B2 (ja) | 2017-03-31 | 2018-03-30 | 末梢神経障害の治療剤又は予防剤 |
SG11201909104P SG11201909104PA (en) | 2017-03-31 | 2018-03-30 | Therapeutic or prophylactic agent for peripheral neuropathies |
US16/496,266 US20200030293A1 (en) | 2017-03-31 | 2018-03-30 | Therapeutic or prophylactic agent for peripheral neuropathies |
AU2018245892A AU2018245892B2 (en) | 2017-03-31 | 2018-03-30 | Therapeutic or prophylactic agent for peripheral neuropathies |
EP18775246.4A EP3603639A4 (en) | 2017-03-31 | 2018-03-30 | THERAPEUTIC OR PROPHYLACTIC FOR PERIPHERAL NEUROPATHIA |
CN201880022139.2A CN110446494A (zh) | 2017-03-31 | 2018-03-30 | 周围神经病变的治疗剂或预防剂 |
CA3057818A CA3057818A1 (en) | 2017-03-31 | 2018-03-30 | Cyclic amine derivatives as therapeutic or prophylactic agents for peripheral neuropathies |
MYPI2019005696A MY201356A (en) | 2017-03-31 | 2018-03-30 | Therapeutic or prophylactic agent for peripheral neuropathies |
KR1020197024768A KR102633957B1 (ko) | 2017-03-31 | 2018-03-30 | 말초신경장해의 치료제 또는 예방제 |
IL269502A IL269502B (en) | 2017-03-31 | 2018-03-30 | A therapeutic or preventive factor for peripheral neuropathies |
RU2019134050A RU2770307C2 (ru) | 2017-03-31 | 2018-03-30 | Терапевтическое или профилактическое средство против периферических невропатий |
BR112019019614A BR112019019614A2 (pt) | 2017-03-31 | 2018-03-30 | agentes terapêuticos ou profiláticos para neuropatias periféricas, induzidas por fármaco, autoimunes, metabólicas ou hereditárias. |
PH12019502261A PH12019502261A1 (en) | 2017-03-31 | 2019-09-30 | Therapeutic or prophylactic agent for peripheral neuropathies |
ZA2019/06762A ZA201906762B (en) | 2017-03-31 | 2019-10-14 | Therapeutic or prophylactic agent for peripheral neuropathies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-071339 | 2017-03-31 | ||
JP2017071339 | 2017-03-31 | ||
JP2017-071329 | 2017-03-31 | ||
JP2017071329 | 2017-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018181860A1 true WO2018181860A1 (ja) | 2018-10-04 |
Family
ID=63678147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/013536 WO2018181860A1 (ja) | 2017-03-31 | 2018-03-30 | 末梢神経障害の治療剤又は予防剤 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20200030293A1 (ja) |
EP (1) | EP3603639A4 (ja) |
JP (1) | JP7163906B2 (ja) |
KR (1) | KR102633957B1 (ja) |
CN (1) | CN110446494A (ja) |
AU (1) | AU2018245892B2 (ja) |
BR (1) | BR112019019614A2 (ja) |
CA (1) | CA3057818A1 (ja) |
IL (1) | IL269502B (ja) |
MX (1) | MX2019010967A (ja) |
MY (1) | MY201356A (ja) |
PH (1) | PH12019502261A1 (ja) |
RU (1) | RU2770307C2 (ja) |
SG (1) | SG11201909104PA (ja) |
TW (1) | TWI774746B (ja) |
WO (1) | WO2018181860A1 (ja) |
ZA (1) | ZA201906762B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020138281A1 (ja) | 2018-12-26 | 2020-07-02 | 東レ株式会社 | アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途 |
WO2021172488A1 (ja) * | 2020-02-28 | 2021-09-02 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
RU2792056C2 (ru) * | 2018-12-26 | 2023-03-16 | Торэй Индастриз, Инк. | Производное циклического амина в качестве средства стимулирования действия адвиллина и новое производное циклического амина и его применение в фармацевтике |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016136944A1 (ja) | 2015-02-27 | 2016-09-01 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
JP2017071339A (ja) | 2015-10-08 | 2017-04-13 | 住友ゴム工業株式会社 | 冬用タイヤ |
JP2017071329A (ja) | 2015-10-08 | 2017-04-13 | 三菱自動車工業株式会社 | 車両暖房システム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101341692B1 (ko) * | 2011-03-16 | 2013-12-20 | 동아에스티 주식회사 | 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물 |
MX2013011932A (es) * | 2011-04-11 | 2013-11-01 | Abbvie Inc | Inhibidores de parp para el tratamiento de cipn. |
JPWO2013147160A1 (ja) * | 2012-03-29 | 2015-12-14 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
NZ702242A (en) * | 2012-05-31 | 2016-03-31 | Asahi Kasei Pharma Corp | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent |
TWI652264B (zh) * | 2013-09-26 | 2019-03-01 | 東麗股份有限公司 | Cyclic amine derivatives and their medical uses |
-
2018
- 2018-03-30 BR BR112019019614A patent/BR112019019614A2/pt active Search and Examination
- 2018-03-30 MY MYPI2019005696A patent/MY201356A/en unknown
- 2018-03-30 EP EP18775246.4A patent/EP3603639A4/en active Pending
- 2018-03-30 RU RU2019134050A patent/RU2770307C2/ru active
- 2018-03-30 JP JP2019510220A patent/JP7163906B2/ja active Active
- 2018-03-30 US US16/496,266 patent/US20200030293A1/en active Pending
- 2018-03-30 SG SG11201909104P patent/SG11201909104PA/en unknown
- 2018-03-30 TW TW107111140A patent/TWI774746B/zh active
- 2018-03-30 CN CN201880022139.2A patent/CN110446494A/zh active Pending
- 2018-03-30 WO PCT/JP2018/013536 patent/WO2018181860A1/ja active Application Filing
- 2018-03-30 MX MX2019010967A patent/MX2019010967A/es unknown
- 2018-03-30 KR KR1020197024768A patent/KR102633957B1/ko active IP Right Grant
- 2018-03-30 AU AU2018245892A patent/AU2018245892B2/en active Active
- 2018-03-30 IL IL269502A patent/IL269502B/en unknown
- 2018-03-30 CA CA3057818A patent/CA3057818A1/en active Pending
-
2019
- 2019-09-30 PH PH12019502261A patent/PH12019502261A1/en unknown
- 2019-10-14 ZA ZA2019/06762A patent/ZA201906762B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016136944A1 (ja) | 2015-02-27 | 2016-09-01 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
JP2017071339A (ja) | 2015-10-08 | 2017-04-13 | 住友ゴム工業株式会社 | 冬用タイヤ |
JP2017071329A (ja) | 2015-10-08 | 2017-04-13 | 三菱自動車工業株式会社 | 車両暖房システム |
Non-Patent Citations (27)
Title |
---|
"Development of pharmaceutical product", vol. 7, 1990, HIROKAWA-SHOTEN LTD., pages: 163 - 198 |
APFEL ET AL., JAMA, vol. 284, 2000, pages 2215 - 2221 |
ARGYRIOU ET AL., CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 82, 2012, pages 51 - 77 |
ATTAL ET AL., EUROPEAN JOURNAL OF NEUROLOGY, vol. 17, 2010, pages l 113 - 1123 |
ATTAL ET AL., PAIN: CLINICAL UPDATES, vol. 18, 2010 |
AZHARY ET AL., AMERICAN FAMILY PHYSICIAN, vol. 81, 2010, pages 887 - 892 |
CHAPLAN ET AL., JOURNAL OF NEUROSCIENCE METHODS, vol. 53, 1994, pages 55 - 63 |
GEWANDTER ET AL., PAIN, vol. 158, 2017, pages 30 - 33 |
HERSHMAN ET AL., JOURNAL OF ONCOLOGY PRACTICE, vol. 10, 2014, pages e421 - e424 |
HUGHES ET AL., THE LANCET, vol. 349, 1997, pages 225 - 230 |
HUGHES ET AL., THE LANCET, vol. 366, 2005, pages 1653 - 1666 |
KUSUNOKI, CLINICAL NEUROLOGY, vol. 49, 2009, pages 956 - 958 |
KUSUNOKI, INTERNAL MEDICINE, THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 102, 2013, pages 1965 - 1970 |
MASUDA RITSUKO: "Classification and diagnosis of neuropathic pain", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 247, no. 4, 2013, pages 317 - 321, XP009517013, ISSN: 0039-2359 * |
MCMAHON ET AL., CURRENT OPINION IN NEUROBIOLOGY, vol. 5, 1995, pages 616 - 624 |
NICKS ET AL., NEUROBIOLOGY OF DISEASE, vol. 70, 2014, pages 224 - 236 |
O'BRIEN ET AL., ILAR JOURNAL, vol. 54, 2014, pages 259 - 272 |
PROGRESS IN MEDICINE, vol. 5, 1985, pages 2157 - 2161 |
RISON ET AL., BIOMED CENTRAL NEUROLOGY, vol. 16, no. 13, 2016 |
SAPORTA ET AL., NEUROLOGIC CLINICS, vol. 31, 2013, pages 597 - 619 |
SCHEMMEL ET AL., JOURNAL OF DIABETES AND ITS COMPLICATION, vol. 24, 2010, pages 354 - 360 |
See also references of EP3603639A4 |
SHINDE ET AL., SUPPORT CARE CANCER, vol. 24, 2016, pages 547 - 553 |
SINGH ET AL., PHARMACOLOGICAL RESEARCH, vol. 80, 2014, pages 21 - 35 |
SOLIVEN, ILAR JOURNAL, vol. 54, 1994, pages 282 - 290 |
SUMITANI MASAHIKO: "What is neuropathic pain? The definition and its clinical significiance", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 247, no. 4, 2013, pages 311 - 316, XP009517010, ISSN: 0039-2359 * |
VILHOLM ET AL., BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 115, 2014, pages 185 - 192 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020138281A1 (ja) | 2018-12-26 | 2020-07-02 | 東レ株式会社 | アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途 |
CN113194947A (zh) * | 2018-12-26 | 2021-07-30 | 东丽株式会社 | 作为Advillin功能促进剂的环状胺衍生物以及新型环状胺衍生物和其药物用途 |
KR20210107713A (ko) | 2018-12-26 | 2021-09-01 | 도레이 카부시키가이샤 | 애드빌린 기능 촉진제로서의 환상 아민 유도체 및 신규 환상 아민 유도체 및 그 의약 용도 |
JPWO2020138281A1 (ja) * | 2018-12-26 | 2021-11-04 | 東レ株式会社 | アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途 |
RU2792056C2 (ru) * | 2018-12-26 | 2023-03-16 | Торэй Индастриз, Инк. | Производное циклического амина в качестве средства стимулирования действия адвиллина и новое производное циклического амина и его применение в фармацевтике |
JP7447803B2 (ja) | 2018-12-26 | 2024-03-12 | 東レ株式会社 | アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途 |
WO2021172488A1 (ja) * | 2020-02-28 | 2021-09-02 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
Also Published As
Publication number | Publication date |
---|---|
TWI774746B (zh) | 2022-08-21 |
KR20190129036A (ko) | 2019-11-19 |
AU2018245892B2 (en) | 2022-02-24 |
EP3603639A1 (en) | 2020-02-05 |
ZA201906762B (en) | 2023-04-26 |
SG11201909104PA (en) | 2019-11-28 |
US20200030293A1 (en) | 2020-01-30 |
RU2019134050A (ru) | 2021-04-30 |
KR102633957B1 (ko) | 2024-02-06 |
EP3603639A4 (en) | 2021-01-27 |
AU2018245892A1 (en) | 2019-10-31 |
JPWO2018181860A1 (ja) | 2020-02-13 |
BR112019019614A2 (pt) | 2020-04-14 |
CA3057818A1 (en) | 2018-10-04 |
MX2019010967A (es) | 2020-01-15 |
MY201356A (en) | 2024-02-20 |
IL269502A (ja) | 2019-11-28 |
RU2019134050A3 (ja) | 2021-05-24 |
IL269502B (en) | 2022-09-01 |
TW201841903A (zh) | 2018-12-01 |
PH12019502261A1 (en) | 2020-07-06 |
JP7163906B2 (ja) | 2022-11-01 |
RU2770307C2 (ru) | 2022-04-15 |
CN110446494A (zh) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA010430B1 (ru) | Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств | |
TW201436791A (zh) | 大麻素與抗精神病藥物組合使用之技術 | |
US9815827B2 (en) | Agent for treatment of schizophrenia | |
JP7429942B2 (ja) | テトラヒドロ-n,n-ジメチル-2,2-ジフェニル-3-フランメタンアミン(anavex2-73)のエナンチオマーならびにシグマ1レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用 | |
JP7163906B2 (ja) | 末梢神経障害の治療剤又は予防剤 | |
EP3804726A1 (en) | Indole compound-containing multiple sclerosis therapeutic or prophylactic agent | |
US20170049777A1 (en) | Compositions, methods and uses for the treatment of diabetic neuropathies | |
HUE027310T2 (en) | Compounds for suppressing the peripheral nerve disorder induced by an anticancer drug | |
US8088799B2 (en) | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | |
US20090068143A1 (en) | Orally effective cannabinoid analogs | |
KR20190087572A (ko) | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
Gosai et al. | Comparative evaluation of Gabapentin and Clonidine for premedication on postoperative analgesia in patient undergoing modified radical mastectomy under general anesthesia | |
US20210346348A1 (en) | Use of carbamate compound for prevention, alleviation or treatment of status epilepticus | |
JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
WO2018181859A1 (ja) | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 | |
IL230174A (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
KR20190013847A (ko) | 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물 | |
US20230172874A1 (en) | Use of cannabidiol for the treatment of insomnia associated to pain | |
WO2015115509A1 (ja) | 多発性硬化症の治療剤又は予防剤 | |
US20220362202A1 (en) | Drug For Treating And Preventing Dementia | |
US20220117941A1 (en) | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder | |
CA2949395A1 (en) | Clearance of amyloid.beta. | |
KR20110071079A (ko) | 침해 수용성 동통의 신규 치료용 의약 조성물 | |
TW200533337A (en) | Pharmaceutical compositions for prevention or treatment of diseases associated with esophageal dysmotility and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18775246 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019510220 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197024768 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3057818 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019019614 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018245892 Country of ref document: AU Date of ref document: 20180330 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018775246 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018775246 Country of ref document: EP Effective date: 20191031 |
|
ENP | Entry into the national phase |
Ref document number: 112019019614 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190919 |